1. Key Messages we are communicating
IBS is a common disease with most patients suffering
from ABC: Abdominal pain, Bloating and
Constipation-
Desired outcome:
 Bring to the doctor’s mind the disease area and the
patient group he sees and their symptoms
•funnel our focus to the right patient category- IBS
with constipation

2. Key Messages: Disease related
 The impact of the symptoms of IBS is
significant:patients quality of life is highly impacted
versus national norms . It is similar to patients with
clinical depression
 Desired outcome:
Make IBS matter- it is not a non- disease it affects lives

3. Key Message: Disease /Patient related
 IBS disrupts activities of every day life- work ,
traveling, socializing, sexual intercourse, domestic and
leisure pursuits, eating and leisure pursuits, eating
certain food as a consequence of their symptoms
 Desired outcome:
 You have circumstances- to create a story ..
 Emphasize that IBS affects lives

4. Key Message: Patient related
 One in three people with IBS miss at least one day of
work per month
 Desired outcome:
 Make it serious- bring to the treating physician the
urgency to treat patients

5. Key Message: Product Position
 Zelmac is the first in a new class of c-IBS therapy, a
5HT4 partial agonist linked to the role of serotonin in
the body as sensorimotor modulator-
 Two required outcomes:
 - peristalsis
 - visceral sensitivity

6. LINK TO THE BENEFIT ON THE KEY
SYMPTOMS

7. Key Message
Rapid and Sustained relief on key symptoms:relief of
abdominal pain/ discomfort,relief of constipation and
improvement in overall well-being

8. Key Message
 Demonstrated efficacy on key c-IBS symptoms :
 Abdominal pain- Severity and number of days
 Bloating- severity and number of days
 Constipation- number of bowel movements and
straining

9. Key Message: Safety
 Proven safety and tolerability profile:
Zelmac has a proven safety in well-controlled clinical
trials of more than than 2,600 patients:no significant
risk for serious AE, safety profile similar to placebo
 low discontinuation rate due to AEs
 diarrhoea is transient and self limiting and rarely led to
discontinuation in studies
 Desired outcome:
 Prescribe with ease and confidence

10. No clinically relevant Drug Drug Interaction
 No known clinically relevant drug interactions:
 Warfarin
 Digoxin
 Oral contraceptives
 theophyline
 Dextromethorphan
 No inhibition on CYT P450 isoenzymes:
 2C8, 2C 19,2E1, 3C4
 Desired outcome:
 Build confidence to prescribe with ease…
 Zelmac= no hassle